Sheila Gujrathi, who joined Bolt Biotherapeutics, Inc. as a Director and Chief Strategy Officer, filed an initial statement of beneficial ownership on October 27, 2026, reporting no securities beneficially owned as of the October 23, 2026 triggering event.

Key Highlights

  • Reporting person: Sheila Gujrathi, identified in the filing as both a Director and Chief Strategy Officer of Bolt Biotherapeutics, Inc.
  • Triggering event date: October 23, 2026, as stated in the filing.
  • Filing date: October 27, 2026, per the signature block.
  • No securities held: The filing states explicitly, "No securities are beneficially owned," with no entries in either Table I (non-derivative securities) or Table II (derivative securities).
  • Issuer and ticker: Bolt Biotherapeutics, Inc., listed on NASDAQ:BOLT.

Gujrathi's Initial Beneficial Ownership Disclosure at Bolt Biotherapeutics

According to the filing, Sheila Gujrathi submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - with the U.S. Securities and Exchange Commission on October 27, 2026. The form was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. The date of the event requiring the statement is listed as October 23, 2026, which the filing identifies as the date Gujrathi became subject to reporting obligations.

The filing discloses that Gujrathi holds dual roles at the company: Director and Chief Strategy Officer. Her address is listed as 900 Chesapeake Drive, Redwood City, California 94063. The form was filed by one reporting person, as indicated by the checked option "Form filed by One Reporting Person."

Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, contain no entries. The filing's explanation of responses states: "No securities are beneficially owned." This means that as of the triggering event date, Gujrathi reported holding no direct or indirect beneficial ownership of any securities of Bolt Biotherapeutics, Inc.

What Was Disclosed

Sheila Gujrathi filed a Form 3 with the SEC on October 27, 2026, in connection with becoming a Director and Chief Strategy Officer of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT). The filing reports no beneficial ownership of any company securities as of October 23, 2026.